skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Find out who’s leading the pack in Oncology drug development, and take a closer look at where the highest success rates are by viewing our webinar recording on Oncology Success Rates. 

 

Effectively manage your portfolio risk by using the comprehensive data sets, including Probability of Overall Success (POS), Likelihood of Approval (LOA), and Phase and Overall Duration, in Pharmapremia. Covering over 500 indications and 7,000 programs, including over 2,200 in oncology, Pharmapremia allows you to generate customized intelligence reports tailored to your company’s goals and needs.

Watch the recording below today!

Read also

  • Scrip: industry news and insights

    Opdivos EU Colorectal Cancer is a Setback but More Than Offset By Potential Gains

    By Ian Schofield 29 Nov 2022

    Bristol-Myers Squibb has withdrawn its EU application to extend Opdivo’s use to metastatic colorectal cancer (mCRC), following a similar move for liver cancer last year. But the mCRC withdrawal is likely to have limited commercial impact and the company is more interested in pursuing the product’s use in combination treatment for this indication.

    Topics Cancer

  • Datamonitor Healthcare: data analysis and insight

    Multiple Myeloma Pricing, Reimbursement, and Access

    14 Nov 2022

    Disease management and treatment programmes change, as research evolves and new discoveries are made. Your market access strategies must evolve too.

    Topics Cancer Drug Development Landscape Reimbursement

  • Datamonitor Healthcare: data analysis and insight

    Acute Myeloid Leukemia Market Outlook Seminar

    By Dominique Fontanilla 14 Nov 2022

    There has been little change to standard treatment for AML in recent years; however, 2017 saw a flurry of new targeted drug approvals, sparking significant market growth. Patient age remains the biggest factor in driving treatment decisions for AML. Cases of AML are expected to increase, and prognosis remains poor – especially among older adults. Drug developers are targeting patient segments with high unmet clinical need to gain access to the AML market and the budget impact of AML is expected to grow considerably.

    Topics Cancer

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.

Contact us for product technical and account support.

  • US Toll-Free   : +1 888 670 8900 
  • US Toll             : +1 212-600-3520
  • UK & Europe : +44 (0) 208 052 0700

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: